Cold atmospheric plasma restores tamoxifen sensitivity in resistant MCF-7 breast cancer cell

Lee, Seungyeon; Lee, Hyun-Kyung; Jeong, Dawoon; Ham, Juyeon; Park, Sung-Bin; Choi, Eun Ha; Kim, Sun Jung

doi:10.1016/j.freeradbiomed.2017.06.017

Cited by 57 publications

(52 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For cell lines that require a higher dose of CAP to effectively reduce viability, that dose may be reduced with the addition of chemotherapy drugs. Lee et al demonstrated that CAP can overcome drug resistance in breast cancer [56] and a similar combination therapy may also further reduce the viability of our cell lines. Future experiments will also include preclinical murine models to determine the efficacy of CAP on tumor reduction and prevention of recurrence.…”

Section: Discussionmentioning

confidence: 79%

The Canady Helios Cold Plasma Scalpel Significantly Decreases Viability in Malignant Solid Tumor Cells in a Dose-Dependent Manner

Rowe¹,

Cheng²,

Ly³

et al. 2018

Plasma

View full text Add to dashboard Cite

Abstract:To determine appropriate treatment doses of cold atmospheric plasma (CAP), the Canady Helios Cold Plasma Scalpel was tested across numerous cancer cell types including renal adenocarcinoma, colorectal carcinoma, pancreatic adenocarcinoma, ovarian adenocarcinoma, and esophageal adenocarcinoma. Various CAP doses were tested consisting of both high (3 L/min) and low (1 L/min) helium flow rates, several power settings, and a range of treatment times up to 5 min. The impact of cold plasma on the reduction of viability was consistently dose-dependent; however, the anti-cancer capability varied significantly between cell lines. While the lowest effective dose varied from cell line to cell line, in each case an 80-99% reduction in viability was achievable 48 h after CAP treatment. Therefore, it is critical to select the appropriate CAP dose necessary for treating a specific cancer cell type.

show abstract

Section: Discussionmentioning

confidence: 79%

The Canady Helios Cold Plasma Scalpel Significantly Decreases Viability in Malignant Solid Tumor Cells in a Dose-Dependent Manner

Rowe¹,

Cheng²,

Ly³

et al. 2018

Plasma

View full text Add to dashboard Cite

show abstract

“…Protein extraction from cultured cells and Western blot analysis were performed as previously described [21]. The following antibodies were used: anti-ELOVL2 (1:500, Bioss, Woburn, MA, USA, bs-7053R), anti-THEM4 (1:500, Abcam, Cambridge, MA, USA, ab106435), anti-β-Actin (1:1000, Bioss, bs-0061R), antiphospho-AKT (1:300, Bioss, bs-5182R), anti-AKT (1:2500, Abcam, ab179463), and HRP-conjugated antirabbit IgG antibody (1:1000, GeneTex, Irvine, CA, USA, GTX213110-01).…”

Section: Western Blot Analysismentioning

confidence: 99%

ELOVL2: a novel tumor suppressor attenuating tamoxifen resistance in breast cancer

Jeong

Ham

Kim

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background To comprehensively understand the molecular mechanism of tamoxifen resistance (TamR) acquisition by epigenetically regulated genes, it is essential to identify pivotal genes by genome-wide methylation analysis and verify their function in xenograft animal model and cancer patients. Methods The MCF-7/TamR breast cancer cell line was developed and a genome-wide methylation array was performed. The methylation and expression of ELOVL2 was validated in cultured cells, xenografted tumor tissue, and breast cancer patients by methylation-specific PCR, qRT-PCR, Western blot analysis, and immunohistochemistry. Deregulation of ELOVL2 and THEM4 was achieved using siRNA or generating stable transfectants. Tam sensitivity, cell growth, and apoptosis were monitored by colorimetric and colony formation assay and flow cytometric analysis. Pathway analysis was performed to generate networks for the differentially methylated genes in the MCF-7/TamR cells and for the differentially expressed genes in the ELOVL2-overexpressing cells. Results Genome-wide methylation analysis in the MCF-7/TamR cells identified elongation of very-long chain fatty acid protein 2 (ELOVL2) to be significantly hypermethylated and downregulated, which was further verified in the tumor tissues from TamR breast cancer patients (n = 28) compared with those from Tam-sensitive (TamS) patients (n = 33) (P < 0.001). Immunohistochemical analysis of tissues from cancer patients showed lower expression of ELOVL2 in the TamR than TamS tissues. Growth of the MCF-7/TamR cells overexpressing ELOVL2 was retarded in cell culture and also in xenograft tumor tissue. Strikingly, ELOVL2 attenuated resistance to Tam up to 70% judged by the colorimetric and colony formation assay and xenograft mouse model. ELOVL2 contributed to the recovery of Tam sensitivity by regulating a group of genes in the AKT and ERα signaling pathways, e.g., THEM4, which plays crucial roles in drug resistance. Conclusions ELOVL2 was hypermethylated and downregulated in TamR breast cancer patients compared with TamS patients. ELOVL2 is responsible for the recovery of Tam sensitivity. AKT- and ERα-hubbed networks are pivotal in ELOVL2 signaling, where THEM4 contributes to the relaying ELOVL2 signaling. This study implies that deregulation of a gene in fatty acid metabolism can lead to drug resistance, giving insight into the development of a new therapeutic strategy for drug-resistant breast cancer.

show abstract

“…Cold atmospheric plasma (CAP) treatments have offered very promising opportunities for wound healing and antiseptics. Moreover, CAP indicated promising anti-neoplastic effects on several tumor entities, e.g., melanoma, glioma, pancreatic, and several gynecological tumors, particularly breast cancer, ovarian cancer, and cervical cancer [2][3][4][5][6][7][8][9][10][11][12][13]. CAP treatment led to sufficient inhibition of cancer cell growth, interestingly, without tissue swelling, inflammation, or pain.…”

Section: Introductionmentioning

confidence: 99%

Cancer-Selective Treatment of Cancerous and Non-Cancerous Human Cervical Cell Models by a Non-Thermally Operated Electrosurgical Argon Plasma Device

Feil

Koch

Utz

et al. 2020

Cancers

View full text Add to dashboard Cite

Cold atmospheric plasma (CAP) treatment is developing as a promising option for local anti-neoplastic treatment of dysplastic lesions and early intraepithelial cancer. Currently, high-frequency electrosurgical argon plasma sources are available and well established for clinical use. In this study, we investigated the effects of treatment with a non-thermally operated electrosurgical argon plasma source, a Martin Argon Plasma Beamer System (MABS), on cell proliferation and metabolism of a tissue panel of human cervical cancer cell lines as well as on non-cancerous primary cells of the cervix uteri. Similar to conventional CAP sources, we were able to show that MABS was capable of causing antiproliferative and cytotoxic effects on cervical squamous cell and adenocarcinoma as well as on non-neoplastic cervical tissue cells due to the generation of reactive species. Notably, neoplastic cells were more sensitive to the MABS treatment, suggesting a promising new and non-invasive application for in vivo treatment of precancerous and cancerous cervical lesions with non-thermally operated electrosurgical argon plasma sources.

show abstract

Cold atmospheric plasma restores tamoxifen sensitivity in resistant MCF-7 breast cancer cell

Cited by 57 publications

References 35 publications

The Canady Helios Cold Plasma Scalpel Significantly Decreases Viability in Malignant Solid Tumor Cells in a Dose-Dependent Manner

The Canady Helios Cold Plasma Scalpel Significantly Decreases Viability in Malignant Solid Tumor Cells in a Dose-Dependent Manner

ELOVL2: a novel tumor suppressor attenuating tamoxifen resistance in breast cancer

Cancer-Selective Treatment of Cancerous and Non-Cancerous Human Cervical Cell Models by a Non-Thermally Operated Electrosurgical Argon Plasma Device

Contact Info

Product

Resources

About